Related Experiment Videos

A functional SNP in EDG2 increases susceptibility to knee osteoarthritis in Japanese

Hideyuki Mototani1, Aritoshi Iida, Masahiro Nakajima

  • 1Laboratory for Bone and Joint Diseases, RIKEN SNP Research Center, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.

Human Molecular Genetics
|March 8, 2008
PubMed

Insights

Osteoarthritis (OA) is linked to a specific gene variant in EDG2, an LPA receptor. This finding suggests the LPA-EDG2 pathway contributes to OA development through cartilage breakdown.

Area of Science:

  • Genetics and Molecular Biology
  • Rheumatology
  • Pharmacology

Background:

  • Osteoarthritis (OA) is a prevalent degenerative joint disease characterized by articular cartilage loss.
  • While several OA-susceptibility genes are known, effective small-molecule drug targets remain limited.
  • G-protein-coupled receptors (GPCRs) represent a potential class of therapeutic targets.

Purpose of the Study:

  • To identify potential OA-susceptibility genes within the GPCR family.
  • To investigate the role of specific single nucleotide polymorphisms (SNPs) in OA pathogenesis.
  • To explore the functional impact of identified genetic variations on gene expression and cellular activity.

Main Methods:

  • A stepwise association study was conducted on 167 SNPs across 44 cartilage-expressed GPCR genes.
  • Luciferase and electrophoretic mobility shift assays were used to assess the functional effects of a key SNP.
  • Gene expression analysis was performed on synovial cells to evaluate the impact of the LPA-EDG2 pathway.

Main Results:

  • A significant association was found between an SNP in the EDG2 promoter region (rs10980705) and knee OA in two independent populations (pooled P = 2.6 x 10(-5)).
  • This SNP demonstrated allelic differences in transcriptional activity and DNA binding in synovial cells, with the OA-associated allele showing enhanced activity.
  • EDG2, encoding an LPA receptor, is highly expressed in the synovium, and its activation by LPA increased inflammatory cytokine and matrix metalloprotease expression.

Conclusions:

  • The LPA-EDG2 signaling pathway is implicated in the pathogenesis of osteoarthritis.
  • The identified SNP (rs10980705) in EDG2 may contribute to OA development by promoting a catabolic process in the synovium.
  • Targeting the LPA-EDG2 pathway could represent a novel therapeutic strategy for osteoarthritis.

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...